Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma

被引：1
|
作者：
Lapuente, Maria [1 ]
Conway, Dawn [2 ]
Wood, Laura S. [3 ]
Kehoe, Kiran [4 ]
Bullock, Andrea Carroll [5 ]
Devgan, Geeta [6 ]
Burns, Kathleen D. [7 ]
机构：
[1] Bartholomews Hosp, London, England
[2] Univ Chicago Med Illinois, Genitourinary Oncol, Chicago, IL USA
[3] Cleveland Clin Ohio, Taussig Canc Ctr, Cleveland, OH USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] North Amer Med Commun EMD Serono, Rockland, MA, Brazil
[6] Pfizer, US Med Affairs, New York, NY USA
[7] City Hope Natl Med Ctr, Natl Canc Ctr, Duarte, CA USA
来源：
CLINICAL JOURNAL OF ONCOLOGY NURSING | 2023年 / 27卷 / 01期
关键词：
avelumab first-line maintenance; bladder cancer; immune-related adverse events; CHEMOTHERAPY; CANCER; CISPLATIN;
D O I：
10.1188/23.CJON.71-80
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND:The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.OBJECTIVES: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.METHODS: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.FINDINGS: Oncology nurses can provide compre-hensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct adminis-tration, and promptly recognizing and managing immune-related adverse events.
引用
收藏
页码：71 / 80
页数：10
相关论文
共 50 条
  • [1] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    Mansinho, Andre
    Cruz, Andreia
    Marconi, Lorenzo
    Pinto, Cidalia
    Augusto, Isabel
    ADVANCES IN THERAPY, 2023, 40 (10) : 4134 - 4150
  • [2] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    André Mansinho
    Andreia Cruz
    Lorenzo Marconi
    Cidália Pinto
    Isabel Augusto
    Advances in Therapy, 2023, 40 : 4134 - 4150
  • [3] Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
    Porte, Fanny
    Granghaud, Anna
    Chang, Jane
    Kearney, Mairead
    Morel, Aya
    Plessala, Ingrid
    Cawston, Helene
    Roiz, Julie
    Xiao, Ying
    Solbes, Marie-Noelle
    Lambert, Prisca
    Ravaud, Alain
    Loriot, Yohann
    Thiery-Vuillemin, Antoine
    Levy, Pierre
    PLOS ONE, 2024, 19 (05):
  • [4] Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
    Critchlow, Simone
    Bullement, Ash
    Crabb, Simon
    Jones, Robert
    Christoforou, Katerina
    Amin, Amerah
    Xiao, Ying
    Kapetanakis, Venediktos
    Benedict, Agnes
    Chang, Jane
    Kearney, Mairead
    Eccleston, Anthony
    FUTURE ONCOLOGY, 2024, 20 (08) : 459 - 470
  • [5] Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
    Grivas, P.
    Grande, E.
    Davis, I. D.
    Moon, H. H.
    Grimm, M. -O.
    Gupta, S.
    Barthelemy, P.
    Thibault, C.
    Guenther, S.
    Hanson, S.
    Sternberg, C. N.
    ESMO OPEN, 2023, 8 (06)
  • [6] Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
    Sridhar, Srikala S.
    Powles, Thomas
    Duran, Miguel A. Climent
    Park, Se Hoon
    Massari, Francesco
    Thiery-Vuillemin, Antoine
    Valderrama, Begona P.
    Ullen, Anders
    Tsuchiya, Norihiko
    Aragon-Ching, Jeanny B.
    Gupta, Shilpa
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Wang, Jing
    Laliberte, Robert J.
    di Pietro, Alessandra
    Costa, Nuno
    Grivas, Petros
    Sternberg, Cora N.
    Loriot, Yohann
    EUROPEAN UROLOGY, 2024, 85 (02) : 154 - 163
  • [7] Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, Begona P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel P.
    Laliberte, Robert
    Wang, Jing
    Huang, Bo
    Davis, Craig
    Fowst, Camilla
    Costa, Nuno
    Blake-Haskins, John A.
    di Pietro, Alessandra
    Grivas, Petros
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13): : 1218 - 1230
  • [8] The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma
    Hoffman-Censits, Jean
    Grivas, Petros
    Powles, Thomas
    Hawley, Jessica
    Tyroller, Karin
    Seeberger, Sonja
    Guenther, Silke
    Jacob, Natalia
    Mehr, Keyvan Tadjalli
    Hahn, Noah M.
    FUTURE ONCOLOGY, 2024, 20 (04) : 179 - 190
  • [9] Avelumab first-line maintenance for advanced or metastatic urothelial carcinoma: analysis from JAVELIN Bladder 100 trial
    Madiraju, Srigita
    Petros, Firas G.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (07) : 1327 - 1328
  • [10] COST-EFFECTIVENESS OF AVELUMAB AS FIRST-LINE MAINTENANCE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN FINLAND
    Karttunen, E.
    Jaaskelainen, S.
    Hervonen, P.
    Chang, J.
    Kearney, M.
    VALUE IN HEALTH, 2022, 25 (01) : S99 - S99
12345